Gary Veytsman, Chief Executive Officer
Mr. Veytsman is CEO of Capital Bioscience, Inc, which he founded in 2007. Under his leadership, Capital Bioscience grew into a leading biotechnology CRO dedicated to connecting researchers from around the world with clinical sites and repositories of high-quality clinically annotated tissue specimens. Earlier in his career, Mr. Veytsman worked with several European companies with a focus on system logistics. Mr. Veytsman studied and received his training in Neuroscience and Biology at George Mason University.
Andrei Malykh, PhD, Chief Scientific Officer
Dr. Andrei Malykh has over 30 years’ experience in research and development of nucleic acid-based technologies. He was formerly the Vice President of Business Development at Fidelity Systems, Inc., where he accomplished development of Fimer technology for direct genomic DNA sequencing in multiple genome projects. Before that, he was senior scientist in a nonprofit research organization, RIGHT, involved in anti-HIV drugs discovery, after serving as visiting fellow in the Laboratory of Tumor Cell Biology at NCI/NIH, where he carried out research in characterization of HIV-1 genetic determinants of cell tropism; sequencing of HIV variants isolated from patients in Russia, and studied effects of combination of anti-HIV agents. His early career includes research in AIDS epidemiology and diagnostics in the Department of Health in St. Petersburg, Russia. Dr. Malykh has coauthored numerous publications, received two patents, and presented at numerous international meetings. He received his PhD from Chemical and Pharmaceutical Institute, St. Petersburg, Russia.
Andrey Pavlov, PhD, Chief Technology Officer
Dr. Pavlov also has over 30 years’ experience broad expertise in development of high throughput analyses, bioinformatics, protein and nucleic acid chemistry, molecular biology, and quantitative bioanalytical assays. He was senior scientist at Fidelity Systems, where he designed novel analytical assays for characterization biological molecules, and, specifically, various nucleic acids, as well as novel PCR procedures. He has a strong background in the field of statistics and design of experiments necessary to draw accurate conclusions from the high throughput analytical data. Prior to Fidelity Systems Dr. Pavlov was Research Assistant Professor at the Dept. of Biochemistry in Tulane University, New Orleans, LA. He received his PhD in Biological Chemistry and Chemical Kinetics from M.V. Lomonosov Moscow State University, Moscow, Russia.
M. Reza Sadaie, PhD, Senior Director, Research and Development
Reza Sadaie, Ph.D. has the knowledge, experience and skill set ranges from basic science to regulatory and product development, and served as consultant at the US-Food and Drug Administration, academia, industry and research institutes. Dr. Sadaie completed his postgraduate degree in Biochemistry at University of Sussex, England. He was awarded Leukemia Society of America Fellowship to do research at Cold Spring Harbor Laboratory under the directorship of Nobel-prize winner James Watson, and Fogarty International Fellowship at National Cancer Institute, NIH. While at NCI and US-FDA, he served as an investigator on multiple projects related to AIDS, diagnostics and antiviral compounds, as well as molecular pathogenic mechanisms of human viruses. He has certificates of training on Investigational New Device/Drugs, blood products, auditing/inspections, FDA laws and requirements. He has worked on safety and efficacy data evaluations, chemistry and manufacturing, orphan drugs for rare diseases, and product license applications for diagnostic test kits, devices and vaccines. Dr. Sadaie has numerous publications and lectured internationally.